The most expensive thing about a "free" tool is usually the person using it.

Every lab has had the meeting. A technique would move the science forward, the software to do it exists, and then the conversation splits two ways: buy the polished commercial package, or adopt the free open-source one that does roughly the same thing. Someone notes the commercial license is expensive. Someone else notes the free one is, well, free. And that is usually where the analysis stops.

It stops in the wrong place, because in a research lab the license fee is rarely the number that decides anything.

I should be upfront about where I'm standing. I've spent my career building scientific software, including commercial packages that sit squarely on the expensive side of exactly this decision. So I have skin in the commercial game. I built this tool anyway — because the decision deserves better than the two numbers people usually compare, and because the honest answer often isn't the one that favors me.

Here is what the standard cost frameworks miss. A researcher's hours have an opportunity cost equal to the experiments, papers, and grants they did not produce while they were installing, debugging, and babysitting a piece of software. In a publish-or-perish environment, "we finally got it running" can cost months of grant clock — and, sometimes, the trainee who burned out getting it to run. None of that appears on an invoice. All of it is real, and for most labs it dwarfs the license.

The generic TCO calculators — the IBM and Gartner enterprise models — don't capture it. They price sysadmin time over a three-to-five-year window and assume corporate IT staffing. There's no "publish once and never touch it again" threshold, no multiplier for the fourth grad student who inherits the pipeline, no cost for a slipped grant clock. The labor rate in those models is a devops salary, not a postdoc's.

The frameworks on the open-source side have the mirror-image blind spot. They measure what it would have cost to build the free tool — replacement value — and treat the adopted tool as a frictionless black box. They say a great deal about the value of open source in the abstract and nothing about the month your postdoc spent getting CUDA to cooperate.

Both sides, in other words, price the software. Neither prices the adoption.

So I built a small tool — TCOscope — to price the adoption. It's an opportunity-cost estimator for the open-source-versus-commercial decision in scientific software, and its entire premise is that the costs that matter are the hidden ones, on both sides.

Open source has hidden costs: the install that turns into a week, the working Python environment that quietly breaks a couple of times a year, the next student who has to learn the whole pipeline from scratch, the CUDA upgrade that fixes one tool and breaks the two that were already running. Commercial has its own: the license, yes, but also the file formats you can't leave, the new modality you can't extend to, the dependence on a vendor's roadmap and release schedule.

The tool models these explicitly rather than hand-waving at them. Installation isn't a single guess — it's a mixture of outcomes, weighted by how hard the tool is to stand up, running from "pip worked in fifteen minutes" out to the cascade tail where days disappear into dependency hell. Maintenance assumes a working install breaks at some rate every year. Every additional person who touches the pipeline pays a handoff cost. And it prices the failure mode nobody budgets for: the upgrade that cascades sideways into tools that were already working fine.

The part I care most about is that it refuses to hand you a single number. It splits cost into three layers you can see through:

• Direct — the cash that leaves the grant: license and hardware.
• Labor — the hours, valued at what they would cost to hire out.
• Research opportunity — those same hours, valued at the papers and grants they might have produced instead.

They are kept separate on purpose. Roll them into one grand total and a skeptic can accuse you of double-counting — is that hour a labor cost or a foregone-paper cost? It is both, depending on the question you're asking, so the tool makes you choose the interpretation instead of burying it. A budget officer reads the Direct line. A PI defending a hire reads Labor. An economist reads all three, with the overlap flagged in plain language.

Here's the case I dogfood: a postdoc segmenting a couple hundred timepoints for a paper, choosing between Cellpose (free) and a commercial package like Imaris, with the license quoted at $22k/yr in the scenario. Run it, and the free tool wins under every interpretation — but the margin is the interesting part. On cash alone, it's a $33k gap. Add the labor, and Cellpose's larger time commitment eats into that, down to about $25k. Add the research-opportunity cost of those extra hours, and it narrows to roughly $11k. Same decision, but now you can see exactly what you're trading — and where it would flip. Here, an academic discount that brought the commercial license below about $5.5k/yr would change the answer.

That last part matters more than the winner. The tool's job isn't to prove open source always wins. It's to tell you which single assumption your decision is actually resting on.

Which is why the bulk of the engineering went into honesty, not arithmetic. Every default value carries a citation and an evidence grade — from "peer-reviewed study that measured this directly" down to "this is my educated guess, treat it as such." Every output flags which inputs you changed from the defaults and names the direction each change pushed the result. And when the answer is being carried mostly by contestable assumptions rather than data, the report says so — in a badge, before you reach the headline.

When I wrote the second worked example, I first drafted it as a win for the commercial side. Then I ran the honest numbers and found it was actually a close call, driven almost entirely by my own priors rather than by anything in the data. I left that in the design doc, correction and all, because catching that is the most useful thing the tool does: it tells you when it doesn't actually know.

It's early. This is a v0 — the equations and worked examples are written down and public, but the calibration still leans mostly on my own labs and a couple of anchors from the reproducibility literature, and I'm more interested right now in whether the framing is right than in defending any particular dollar figure. The code is MIT; the methodology is open and version-pinned, so anyone — including the vendors on the expensive side of the comparison — can check the math or argue with the priors. Reproducibility is the whole point: a result you disagree with is also a result you can re-run with your own assumptions.

If you've ever sat in that meeting and felt that the "obvious" cheaper option wasn't obviously cheaper, that instinct was right. The cost was real. It just wasn't on the quote.

Try the Buy vs. Build Calculator — free, no email required. Join the discussion on LinkedIn.